# Study of Neoantigen-specific Adoptive T Cell Therapy for Newly Diagnosed MGMT Negative Glioblastoma Multiforme (GBM)

> **NCT05685004** · PHASE2,PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **TVAX Biomedical** · enrollment: 120 (estimated)

## Conditions studied

- Glioblastoma Multiforme of Brain

## Interventions

- **BIOLOGICAL:** TVI-Brain-1
- **PROCEDURE:** Standard of Care
- **RADIATION:** Radiotherapy
- **DRUG:** Temozolomide

## Key facts

- **NCT ID:** NCT05685004
- **Lead sponsor:** TVAX Biomedical
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2023-09-15
- **Primary completion:** 2026-12
- **Final completion:** 2027-03
- **Target enrollment:** 120 (ESTIMATED)
- **Last updated:** 2025-07-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05685004

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05685004, "Study of Neoantigen-specific Adoptive T Cell Therapy for Newly Diagnosed MGMT Negative Glioblastoma Multiforme (GBM)". Retrieved via AI Analytics 2026-07-19 from https://api.ai-analytics.org/clinical/NCT05685004. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*